Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free ABUS Stock Alerts

Arbutus Biopharma (ABUS) Short Interest Ratio & Short Volume

Arbutus Biopharma logo
$4.38 -0.09 (-2.01%)
Closing price 04:00 PM Eastern
Extended Trading
$4.38 0.00 (0.00%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Arbutus Biopharma Short Interest Overview

As of July 15, 2026, Arbutus Biopharma (ABUS) had a short interest of 19.65 million shares sold short, representing 12.42% of the public float. This marks a 14.85% increase in short interest since the prior report. The short interest ratio (days to cover) is 7.4, meaning it would take 7.4 days of the average trading volume of 2.56 million shares to cover all short positions.

Current Short Interest
19,653,287 shares
Previous Short Interest
17,111,453 shares
Change Vs. Previous Month
14.85%
Dollar Volume Sold Short
$89.62 million
Short Interest Ratio
7.4 Days to Cover
Last Record Date
July 15, 2026
Outstanding Shares
197,540,000 shares
Short Percent of Float
12.42%
Today's Trading Volume
876,393 shares
Average Trading Volume
2,555,921 shares
Today's Volume Vs. Average
34%
Short Selling Arbutus Biopharma?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Arbutus Biopharma and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

ABUS Short Interest Over Time

ABUS Days to Cover Over Time

ABUS Percentage of Float Shorted Over Time

Arbutus Biopharma Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/15/202619,653,287 shares $89.62 million +14.9%12.4%7.4 $4.56
6/30/202617,111,453 shares $82.13 million -2.4%10.8%4.89 $4.80
6/15/202617,522,670 shares $75.70 million +3.2%11.1%13.96 $4.32
5/29/202616,982,764 shares $77.44 million +3.3%10.7%9.18 $4.56
5/15/202616,438,082 shares $69.70 million -7.4%10.4%17.08 $4.24
4/30/202617,743,389 shares $74.52 million -0.3%11.2%7.17 $4.20
4/15/202617,803,913 shares $79.76 million +10.1%11.3%11.44 $4.48
3/31/202616,174,093 shares $72.78 million -1.4%10.2%7.04 $4.50
3/13/202616,405,599 shares $69.89 million +11.2%10.7%4.18 $4.26
2/27/202614,756,509 shares $68.77 million -1.6%9.3%9.52 $4.66
2/13/202614,998,521 shares $59.69 million +10.6%9.5%6.43 $3.98
1/30/202613,558,940 shares $56.00 million +3.8%8.8%7.47 $4.13
1/15/202613,067,041 shares $61.42 million +4.2%8.5%12.17 $4.70
12/31/202512,535,638 shares $60.30 million +16.7%8.2%8.63 $4.81
12/15/202510,740,954 shares $53.17 million -4.2%7.0%9.28 $4.95
11/28/202511,206,745 shares $49.37 million +6.1%7.3%9.87 $4.41
11/14/202510,563,698 shares $47.75 million +6.5%6.9%10.74 $4.52
10/31/20259,916,540 shares $46.91 million +0.5%6.5%10.35 $4.73
10/15/20259,860,000 shares $44.07 million -2.8%6.5%9.1 $4.47
9/30/202510,140,000 shares $46.04 million -9.1%N/A9.7 $4.54
9/15/202511,160,000 shares $50.55 million +5.8%N/A10.4 $4.53
8/31/202510,550,000 shares $39.14 million -15.7%6.9%11.5 $3.71
8/15/202512,510,000 shares $42.16 million -3.6%N/A16.1 $3.37
7/31/202512,980,000 shares $42.57 million -4.8%8.5%17.1 $3.28
7/15/202513,640,000 shares $42.69 million -0.9%N/A17.2 $3.13
6/30/202513,770,000 shares $42.55 million +7.2%9.0%15.5 $3.09
6/15/202512,840,000 shares $45.33 million +0.7%8.4%13.8 $3.53
5/31/202512,750,000 shares $42.84 million +10.9%7.0%13.5 $3.36
5/15/202511,500,000 shares $35.88 million +2.8%6.3%10.7 $3.12
4/30/202511,190,000 shares $39.72 million +1.3%N/A10.9 $3.55
4/15/202511,050,000 shares $34.92 million +12.2%6.1%11.1 $3.16
3/31/20259,850,000 shares $34.38 million +2.9%5.4%10.1 $3.49
3/15/20259,570,000 shares $31.58 million +13.8%5.3%10.9 $3.30
2/28/20258,410,000 shares $29.01 million +16.6%4.6%9.8 $3.45
2/15/20257,210,000 shares $23.72 million +7.3%4.0%8.8 $3.29
1/31/20256,720,000 shares $22.38 million +1.2%N/A8.1 $3.33
1/15/20256,640,000 shares $21.78 million +11.6%N/A8 $3.28
12/31/20245,950,000 shares $19.46 million -0.3%N/A6.8 $3.27
12/15/20245,970,000 shares $20.78 million +2.6%N/A6.9 $3.48
11/30/20245,820,000 shares $20.14 million -4.0%N/A5.7 $3.46
Elon's next move will be bigger than the IPO – and it could happen any day now (Ad)

Hedge fund legend Larry Benedict - who delivered a 279% return on cash in 2025 and went on a 20-year winning streak - says the SpaceX IPO wasn't the main event. It was the trigger. He's identified what he calls the 'Final Phase of Elon's Master Plan,' and one specific ticker he believes could see billions forced into it within days. It's not SpaceX, Tesla, or any company you'd associate with Elon Musk. Larry is revealing the ticker free today.tc pixel

Watch Larry Benedict's presentation and get the one ticker now
11/15/20246,060,000 shares $22.06 million -7.3%N/A5.3 $3.64
10/31/20246,540,000 shares $25.15 million -16.1%N/A5.9 $3.85
10/15/20247,790,000 shares $32.02 million +5.8%N/A6.9 $4.11
9/30/20247,360,000 shares $28.34 million +12.2%N/A6.6 $3.85
9/15/20246,560,000 shares $29.32 million +8.3%N/A5.6 $4.47
8/31/20246,060,000 shares $23.45 million -8.7%N/A5.8 $3.87
8/15/20246,640,000 shares $24.90 million -2.4%N/A6.6 $3.75
7/31/20246,800,000 shares $25.64 million -3.1%N/A6.8 $3.77
7/15/20247,020,000 shares $26.33 million +16.8%N/A7.3 $3.75
6/30/20246,010,000 shares $18.57 million +11.9%N/A6.1 $3.09
6/15/20245,370,000 shares $16.86 million +6.8%N/A4.2 $3.14
5/31/20245,030,000 shares $16.90 million -5.8%N/A4.1 $3.36
5/15/20245,340,000 shares $15.01 million -8.1%N/A4.6 $2.81
4/30/20245,810,000 shares $15.86 million +12.4%N/A4.3 $2.73
4/15/20245,170,000 shares $15.35 million +13.6%N/A3.7 $2.97
3/31/20244,550,000 shares $11.74 million +10.2%N/A3.4 $2.58
3/15/20244,130,000 shares $10.82 million +1.5%N/A4.4 $2.62
2/29/20244,070,000 shares $11.40 million +10.3%N/A4.2 $2.80
2/15/20243,690,000 shares $10.74 million -39.7%N/A3.8 $2.91
1/31/20246,120,000 shares $14.50 million -4.8%N/A7.3 $2.37
1/15/20246,430,000 shares $14.85 million +3.4%N/A9.5 $2.31
12/31/20236,220,000 shares $15.55 million +0.5%N/A9.1 $2.50
12/15/20236,190,000 shares $13.87 million +0.2%N/A9.2 $2.24
11/30/20236,180,000 shares $12.67 million -8.2%N/A9.4 $2.05
11/15/20236,730,000 shares $12.38 million +6.7%N/A10.6 $1.84
10/31/20236,310,000 shares $11.55 million +9.4%N/A10.4 $1.83
10/15/20235,770,000 shares $10.73 million -16.1%N/A9.4 $1.86
9/30/20236,880,000 shares $13.97 million +18.6%N/A11.2 $2.03
9/15/20235,800,000 shares $11.83 million +12.0%N/A9.4 $2.04
8/31/20235,180,000 shares $10.52 million +0.8%N/A8.3 $2.03
8/15/20235,140,000 shares $10.23 million +5.1%N/A8.4 $1.99
7/31/20234,890,000 shares $10.61 million +0.8%N/A8.5 $2.17
7/15/20234,850,000 shares $10.82 million -0.8%N/A7.8 $2.23
6/30/20234,890,000 shares $11.25 million +12.7%N/A6.8 $2.30
6/15/20234,340,000 shares $10.59 million +2.1%N/A5.8 $2.44
5/31/20234,250,000 shares $10.58 million -0.9%N/A5.3 $2.49
5/15/20234,290,000 shares $10.98 million +8.3%N/A4.7 $2.56
4/30/20233,960,000 shares $9.94 million -7.0%N/A4.2 $2.51
4/15/20234,260,000 shares $12.23 million -13.9%N/A4.7 $2.87
3/31/20234,950,000 shares $15.00 million +5.5%N/A5.4 $3.03
3/15/20234,690,000 shares $14.21 million +15.8%N/A5 $3.03
2/28/20234,050,000 shares $11.26 million +1.5%N/A4.5 $2.78
2/15/20233,990,000 shares $10.85 million -7.4%N/A4.5 $2.72
1/31/20234,310,000 shares $12.97 million -8.5%N/A4.6 $3.01
1/15/20234,710,000 shares $13.42 million -0.6%N/A4.9 $2.85
12/30/20224,740,000 shares $11.04 million +23.1%N/A4.6 $2.33
12/15/20223,850,000 shares $10.43 million -4.0%N/A4.1 $2.71
11/30/20224,010,000 shares $9.42 million +7.2%N/A4.4 $2.35
11/15/20223,740,000 shares $10.43 million -10.3%N/A4.3 $2.79
10/31/20224,170,000 shares $9.76 million -0.7%N/A5.2 $2.34
Your book is inside (Ad)

The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel

Download your copy now.
10/15/20224,200,000 shares $9.20 million +2.2%N/A5.4 $2.19
9/30/20224,110,000 shares $7.85 million +7.6%N/A5.6 $1.91
9/15/20223,820,000 shares $8.82 million -2.6%N/A4.7 $2.31
8/31/20223,920,000 shares $8.70 million -11.1%N/A4.7 $2.22
8/15/20224,410,000 shares $11.16 million -7.4%N/A4.8 $2.53
7/31/20224,760,000 shares $11.00 million -7.4%N/A4.5 $2.31
7/15/20225,140,000 shares $13.06 million -2.5%N/A4.8 $2.54
6/30/20225,270,000 shares $14.28 million +7.1%N/A4.5 $2.71
6/15/20224,920,000 shares $12.55 million -7.9%N/A3.9 $2.55
5/31/20225,340,000 shares $12.98 million +6.6%N/A3.8 $2.43
5/15/20225,010,000 shares $11.57 million -5.8%N/A2.9 $2.31
4/30/20225,320,000 shares $12.40 million -8.3%N/A2.9 $2.33
4/15/20225,800,000 shares $15.95 million -12.8%N/A2.6 $2.75
3/31/20226,650,000 shares $19.82 million +0.3%N/A2.7 $2.98
3/15/20226,630,000 shares $18.96 million -8.8%N/A2.3 $2.86
2/28/20227,270,000 shares $23.26 million +3.0%N/A1.8 $3.20
2/15/20227,060,000 shares $22.95 million +4.1%N/A0.7 $3.25
1/31/20226,780,000 shares $19.05 million +73.0%N/A0.7 $2.81
1/15/20223,920,000 shares $12.98 million -13.9%N/A0.4 $3.31
12/31/20214,550,000 shares $17.70 million -43.6%N/A0.5 $3.89
12/15/20218,060,000 shares $32.97 million +253.5%N/A0.8 $4.09
11/30/20212,280,000 shares $7.30 million -4.2%N/A0.2 $3.20
11/15/20212,380,000 shares $8.00 million -15.0%N/A1 $3.36
10/29/20212,800,000 shares $11.28 million +0.7%N/A1.1 $4.03
10/15/20212,780,000 shares $11.34 million No Change3.5%1.1 $4.08
9/30/20212,780,000 shares $11.93 million -24.9%3.5%1.2 $4.29
9/15/20213,700,000 shares $15.61 million -6.1%4.6%1.6 $4.22
8/31/20213,940,000 shares $13.51 million -5.1%4.9%2.4 $3.43
8/13/20214,150,000 shares $12.74 million -26.2%5.2%2.5 $3.07
7/30/20215,620,000 shares $15.12 million +14.9%7.3%3.6 $2.69

ABUS Short Interest - Frequently Asked Questions

Short interest is the volume of Arbutus Biopharma shares that have been sold short but have not yet been closed out or covered. As of July 15th, traders have sold 19,653,287 shares of ABUS short. 12.42% of Arbutus Biopharma's shares are currently sold short. Learn More on Arbutus Biopharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ABUS shares currently have a short interest ratio of 7.4. Learn More on Arbutus Biopharma's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.42% of Arbutus Biopharma's floating shares are currently sold short.

Arbutus Biopharma saw a increase in short interest in July. As of July 15th, there was short interest totaling 19,653,287 shares, an increase of 14.9% from the previous total of 17,111,453 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

12.42% of Arbutus Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Arbutus Biopharma: Arcutis Biotherapeutics, Inc. (11.97%), Telix Pharmaceuticals Limited (0.09%), Organon & Co. (6.29%), Structure Therapeutics Inc. Sponsored ADR (9.24%), Arcus Biosciences, Inc. (10.81%), Enliven Therapeutics, Inc. (14.64%), IDEAYA Biosciences, Inc. (11.43%), MBX Biosciences, Inc. (17.61%), Disc Medicine, Inc. (19.85%), Ultragenyx Pharmaceutical Inc. (14.39%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($73.09 billion), Invesco QQQ ($48.11 billion), iShares Russell 2000 ETF ($23.61 billion), Sandisk Corporation ($12.69 billion), Nebius Group N.V. ($12.18 billion), Western Digital Corporation ($11.95 billion), SPDR S&P Biotech ETF ($11.73 billion), Quhuo Limited Sponsored ADR ($9.74 billion), VanEck Semiconductor ETF ($9.57 billion), and Financial Select Sector SPDR Fund ($8.43 billion). View all of the most shorted stocks.

Short selling ABUS is an investing strategy that aims to generate trading profit from Arbutus Biopharma as its price is falling. ABUS shares are trading down $0.09 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Arbutus Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ABUS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ABUS, twice per month. The most recent reporting period available is July, 15 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like ABUS:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:ABUS) was last updated on 7/24/2026 by MarketBeat.com Staff.
From Our Partners
The number they’re trying to hide from you
The 10-year Treasury yield is nearing 4.4 percent, a level analyst Garrett Goggin says could force the Federal...
Golden Portfolio | Sponsoredtc pixel
Elon says “don’t save money.” Is he right?
Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal ...
Freedom Financial | Sponsoredtc pixel
Have you seen Elon’s new “supercurrency”? (It affects you)
Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...
StocksToTrade | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Two states are racing to block Elon Musk’s new money
New York and Massachusetts are racing to block Elon Musk's newest project, with Senator Elizabeth Warren fight...
Banyan Hill Publishing | Sponsoredtc pixel
This tiny piece of glass could be bigger than GPUs
A tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...
Brownstone Research | Sponsoredtc pixel
The market told you. In writing. Early.
Some trading losses are surprises. Others are scheduled months, even a year, in advance and published for free...
Profits Run | Sponsoredtc pixel
Trump’s emergency dollar reset
Bloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...
Porter & Company | Sponsoredtc pixel